Translational Research

1. Can Kinetics Provide Detailed Information About Binding Interactions? 2/17/2022

   See the potential value kinetics brings to deepen the understanding of biological processes.

2. Plasmid Complexity And The Push For Stronger CGT Material Control 4/1/2026

   In this segment of Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, were joined by Cell & Gene Chief Editor Erin Harris to discuss why complex materials such as plasmid DNA are critical yet challenging in cell and gene therapy because small variations (e.g., sequence or structure) can significantly impact the final product, and current analytical tools often struggle to fully characterize them.

3. Major Advancements In mRNA 1/29/2024

   Experts on this Cell & Gene live event discuss the major scientific biological advances in understanding the potential for mRNA-based immunotherapies vaccines for cancer over the last 2 years.

4. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

   This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

5. Electroporation As A Method For Genetic Modification 11/9/2024

   In this clip, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics explain why electroporation has a higher gene editing efficiency than that of the viral vector method.

6. Base Editing's Advantages When Combined With Non-Viral Delivery Methods 11/9/2024

   In this segment, Paul Kopesky of Beam Therapeutics shares information on the advantages base editing has over other gene editing approaches when combined with non-viral delivery methods as well as how Beam addresses the challenge of achieving therapeutic levels of editing and target tissues using non-viral delivery systems.

7. Analytics & Assays: Defining mRNA Therapeutic Impurities Early & Often 12/5/2023

   mRNA therapeutics present a whole new safety paradigm not seen in vaccine applications. In this segment, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address the nuances of mRNA therapeutic analytics and assays.

8. Streamline Your mRNA Purification Steps 3/4/2025

   Ensure your mRNA's stability and effectiveness post-transcription with advanced filtration and chromatography techniques to enhance purity and recovery, which delivers high-quality mRNA for superior therapeutics and vaccines.

9. Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process 4/21/2025

   Help shape the future of medicine by building better, safer cell therapies. See how expertise in scalable, GMP-compliant cell engineering can effectively mitigate clinical development risks.

10. High Efficiency Cell Engineering From Concept To Clinic 4/21/2025

    Discover how highly efficient and scalable methods for engineering cells are accelerating the development and delivery of next-generation cell-based treatments for patients.